TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31531960

Group type: EXPERIMENTAL
Intervention: Modified-release prednisone (MR)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Immediate-release prednisolone (IR)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both MR and IR
Number of subjects: 12
Study: 28243723

Group type: EXPERIMENTAL
Intervention: PBM-LED therapy
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (RT without PBM-LED)
Number of subjects: 70
Study: 26209223

Group type: EXPERIMENTAL
Intervention: Hormone Therapy (HT) continuation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 17β‐estradiol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hormone Therapy (HT) discontinuation
Number of subjects: 0
Study: 25502511

Group type: EXPERIMENTAL
Intervention: Agalsidase beta 1 mg/kg biweekly
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 22567652

Group type: EXPERIMENTAL
Intervention: Maxillary removable appliances and face masks
Number of subjects: 43

Group type: COMPARATOR
Intervention: Maxillary fixed appliances and face masks
Number of subjects: 43
Study: 19954719

Group type: EXPERIMENTAL
Intervention: Tacrolimus (3 mg/day, 0.04 - 0.075 mg/kg)
Number of subjects: 11
Study: 17578464

Group type: EXPERIMENTAL
Intervention: Intravenous clonidine 2 microg/kg
Number of subjects: 300

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 300
Study: 15187493

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil
Number of subjects: 51

Group type: COMPARATOR
Intervention: Combination of enalapril and candesartan
Number of subjects: 51
Study: 12236051

Group type: EXPERIMENTAL
Intervention: Bacterial immunostimulant (Enterococcus faecalis Bacteriae of human origin, Symbioflor 1, 3 x 30 drops/day)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study: 9771255

Group type: EXPERIMENTAL
Intervention: NovoPen
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: BD-Pen
Number of subjects: 20

Group type: COMPARATOR
Intervention: Syringe
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: All devices
Number of subjects: 20
Study: 1347229

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.6 micrograms kg‐1
Number of subjects: 24

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 24
Study: 3084237

Group type: EXPERIMENTAL
Intervention: Hyperventilation with a rebreathing rate of 30 min‐1 and tidal volume corresponding to 60% of the subject's vital capacity.
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Increased tidal volume (higher than 60% of vital capacity).
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Initial and final measurements after hyperventilation.
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Variations in rebreathing rate from 25 to 35 min‐1 and tidal volume changes of +/- 0.5.
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Repeated measurements in seven subjects.
Number of subjects: 14
Study: 30449232

Group type: EXPERIMENTAL
Intervention: Support for honor-based violence (HBV) in principle
Number of subjects: 1050

Group type: EXPERIMENTAL
Intervention: Support for legislation permitting HBV
Number of subjects: 1050

Group type: EXPERIMENTAL
Intervention: Correlates of views toward honor-based crimes
Number of subjects: 1050

Group type: EXPERIMENTAL
Intervention: Demographic attributes
Number of subjects: 1050
Study: 31306589

Group type: EXPERIMENTAL
Intervention: PEEK interference screws
Number of subjects: 133

Group type: COMPARATOR
Intervention: Titanium interference screws
Number of subjects: 133
Study: 29337125

Group type: EXPERIMENTAL
Intervention: Tridyne
Number of subjects: 158

Group type: COMPARATOR
Intervention: Gelfoam Plus
Number of subjects: 158
Study: 27687355

Group type: EXPERIMENTAL
Intervention: Entropy monitor (Group EM)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard clinical monitoring (Group CM)
Number of subjects: 120
Study: 24220692

Group type: COMPARATOR
Intervention: Shock wave lithotripsy (SWL)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Flexible ureterorenoscopy (F‐URS)
Number of subjects: 140
Study: 22011217

Group type: EXPERIMENTAL
Intervention: EE/DRSP (ethinyl-estradiol 30 mcg/drospirenone 3 mg)
Number of subjects: 59

Group type: COMPARATOR
Intervention: EE/CMA (ethinyl-estradiol 30 mcg/chlormadinone acetate 2 mg)
Number of subjects: 59
Study: 21056810

Group type: EXPERIMENTAL
Intervention: C(et) of remifentanil 0.5 ng/mL
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: C(et) of remifentanil 1 ng/mL
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: C(et) of remifentanil 1.5 ng/mL
Number of subjects: 66
Study: 17985581

Group type: EXPERIMENTAL
Intervention: Magnesium group 1 (Mg1 G) - 50 mg kg(‐1) preoperatively followed by 8 mg kg(‐1) h(‐1) infusion
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Magnesium group 2 (Mg2 G) - 50 mg kg(‐1) preoperatively followed by 16 mg kg(‐1) h(‐1) infusion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group - isotonic solution
Number of subjects: 60
Study: 15659503

Group type: EXPERIMENTAL
Intervention: Attenuated-dose (AD) regimen: cisplatin 25 mg/m² on days 1 and 2, etoposide 60 mg/m² on days 1, 2, and 3 every 3 weeks.
Number of subjects: 95

Group type: COMPARATOR
Intervention: Full-dose (FD) regimen: cisplatin 40 mg/m² on days 1 and 2, etoposide 100 mg/m² on days 1, 2, and 3 every 3 weeks, plus lenograstim 5 mg/kg days 5 through 12, every 3 weeks.
Number of subjects: 95
Study: 12477996

Group type: EXPERIMENTAL
Intervention: Megestrol acetate (160 mg twice per day oral suspension)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 262
Study: 9534963

Group type: EXPERIMENTAL
Intervention: Granulocyte‐macrophage colony‐stimulating factor (GM‐CSF)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Azithromycin alone
Number of subjects: 8
Study: 7498232

Group type: EXPERIMENTAL
Intervention: 99mTc‐tetrofosmin
Number of subjects: 5
Study: 2317419

Group type: EXPERIMENTAL
Intervention: Inhalation induction with isoflurane and rectal thiopentone premedication
Number of subjects: 100

Group type: COMPARATOR
Intervention: Inhalation induction with isoflurane without premedication
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Inhalation induction with halothane and rectal thiopentone premedication
Number of subjects: 100

Group type: COMPARATOR
Intervention: Inhalation induction with halothane without premedication
Number of subjects: 100
Study: 6773613

Group type: EXPERIMENTAL
Intervention: Nifedipine 30 mg/day
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nifedipine 60 mg/day
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Propranolol 240 mg/day
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Propranolol 480 mg/day
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Combination of propranolol and nifedipine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 31872563

Group type: EXPERIMENTAL
Intervention: Home-based telehealth (HBT)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Office-based telehealth (OBT)
Number of subjects: 175

Group type: COMPARATOR
Intervention: In-home-in-person (IHIP)
Number of subjects: 175
Study: 28285571

Group type: EXPERIMENTAL
Intervention: Active treatment using visual imagery under conditions of rote repetition and spaced retrieval
Number of subjects: 20

Group type: COMPARATOR
Intervention: No-treatment attention control
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Active treatment using visual imagery
Number of subjects: 20
Study: 28365428

Group type: EXPERIMENTAL
Intervention: Structured case management (CM)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 121
Study: 26402079

Group type: EXPERIMENTAL
Intervention: 2.3 g ω3 FA daily for 6 months
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 174
Study: 23733403

Group type: EXPERIMENTAL
Intervention: Extended-release memantine (28 mg, once daily)
Number of subjects: 677
Study: 22011532

Group type: EXPERIMENTAL
Intervention: Intervention group with repeated MRSA screening, contact and droplet isolation precautions, and decontamination with nasal mupirocin and chlorhexidine body wash for MRSA-positive patients.
Number of subjects: 500

Group type: COMPARATOR
Intervention: Standard precautions protocol without communication of repeated MRSA screening results.
Number of subjects: 500
Study: 19515737

Group type: EXPERIMENTAL
Intervention: Flaxseed interventions
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Whole flaxseed
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Lignan supplements
Number of subjects: 28

Group type: COMPARATOR
Intervention: Flaxseed oil
Number of subjects: 28
Study: 17088453

Group type: EXPERIMENTAL
Intervention: Acipimox (inhibitor of lipolysis)
Number of subjects: 18
Study: 15474700

Group type: EXPERIMENTAL
Intervention: Picotamide (600 mg bid)
Number of subjects: 1209

Group type: COMPARATOR
Intervention: Aspirin (320 mg od)
Number of subjects: 1209
Study: 11197402

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide at 5 ppm
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide at 20 ppm
Number of subjects: 7
Study: 9232132

Group type: EXPERIMENTAL
Intervention: Alfentanil (20 micrograms/kg intravenously) after midazolam (1 mg intravenously)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Alfentanil (20 micrograms/kg intravenously) after midazolam (1 mg intravenously) with rifampin induction
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Alfentanil (20 micrograms/kg intravenously) after midazolam (1 mg intravenously) with troleandomycin inhibition
Number of subjects: 9

Group type: COMPARATOR
Intervention: Alfentanil clearance in controls
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Alfentanil clearance in men receiving rifampin
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Alfentanil clearance in men receiving troleandomycin
Number of subjects: 9
Study: 8007760

Group type: EXPERIMENTAL
Intervention: Cocaine hydrochloride (10 mg unit doses, intranasally)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Cocaine vs. varying amounts of money (0-$2.00/choice)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo (intranasally)
Number of subjects: 4
Study: 2592963

Group type: EXPERIMENTAL
Intervention: Social skills training plus homework
Number of subjects: 28

Group type: COMPARATOR
Intervention: Group discussion plus homework
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 28
Study: 5792915

Group type: EXPERIMENTAL
Intervention: Phentolamine (alpha-adrenergic blockade)
Number of subjects: 0
Study: 31229240

Group type: EXPERIMENTAL
Intervention: Pexidartinib (1000 mg per day for 2 weeks, then 800 mg per day for 22 weeks)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Pexidartinib
Number of subjects: 120
Study: 29165011

Group type: EXPERIMENTAL
Intervention: Motor imagery intervention (imagined walking, imagined talking, imagined walking while talking)
Number of subjects: 48
Study: 26515147

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 180

Group type: COMPARATOR
Intervention: Thiopental sodium
Number of subjects: 180
Study: 23333695

Group type: EXPERIMENTAL
Intervention: Video
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Video plus commentary
Number of subjects: 170

Group type: COMPARATOR
Intervention: Written Description
Number of subjects: 170
Study: 21971662

Group type: EXPERIMENTAL
Intervention: L‐Ala‐Gln (20% solution, 0.5g/Kg, adding saline to complete 100ml)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal saline (100 ml, delivered intravenously over 3 hours)
Number of subjects: 30
Study: 19968175

Group type: EXPERIMENTAL
Intervention: Rib autograft for reconstructing iliac crest (RG group, n = 25)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Non-reconstruction group (NRG, n = 29)
Number of subjects: 54
Study: 17197214

Group type: EXPERIMENTAL
Intervention: ketamine/remifentanil (KET/REMI)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: ketamine/remifentanil (KET/REMI) at low REMI target concentration (1ng/ml)
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo/remifentanil (P/REMI) at 2ng/ml target concentration
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: ketamine/remifentanil (KET/REMI) at 2ng/ml target concentration
Number of subjects: 20

Group type: COMPARATOR
Intervention: ketamine/remifentanil (KET/REMI) and placebo/remifentanil (P/REMI)
Number of subjects: 20
Study: 15715026

Group type: EXPERIMENTAL
Intervention: Cognitive‐Behavioral Treatment (CBT Group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Observation Group (waiting)
Number of subjects: 50
Study: 11597824

Group type: EXPERIMENTAL
Intervention: Paroxetine 20‐40 mg
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Paroxetine 20‐40 mg with pindolol
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study: 9150858

Group type: EXPERIMENTAL
Intervention: S‐naproxen betainate sodium salt monohydrate (naproxen‐betaNa), 575 mg capsule containing 342 mg of S‐naproxen
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sodium salt of S‐naproxen (reference), two 275 mg tablets containing 502 mg of S‐naproxen
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both formulations (test and reference)
Number of subjects: 12
Study: 8205295

Group type: EXPERIMENTAL
Intervention: Isradipine (2.5 or 5.0 mg twice daily)
Number of subjects: 883

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 883
Study: 3548930

Group type: EXPERIMENTAL
Intervention: Ticarcillin/clavulanic acid (3 g ticarcillin and 100 mg clavulanic acid every 8 hours)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Metronidazole/netilmicin (500 mg metronidazole and 80 mg netilmicin every 8 hours)
Number of subjects: 92
Study: 30552249

Group type: EXPERIMENTAL
Intervention: VA Telederm mobile app
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard process (workstation-based store-and-forward teledermatology)
Number of subjects: 0
Study: 27265725

Group type: EXPERIMENTAL
Intervention: Adjunctive brivaracetam (BRV) 50–200 mg/day
Number of subjects: 2186
Study: 25326180

Group type: EXPERIMENTAL
Intervention: Therapeutic nuclear magnetic resonance (tNMR) with a magnetic flux density of 2.3 mT and a frequency of 85 kHz, 7 sessions
Number of subjects: 94

Group type: COMPARATOR
Intervention: Standard non-surgical therapy + sham treatments (Control Group)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Standard non-surgical therapy + tNMR (Treatment Group)
Number of subjects: 94
Study: 23591603

Group type: EXPERIMENTAL
Intervention: Smoking withdrawal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ad libitum smoking
Number of subjects: 0
Study: 22104547

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Number of subjects: 4038

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4038
Study: 19239400

Group type: EXPERIMENTAL
Intervention: Injection diclofenac sodium 75 mg/ml (test formulation) given as an intradeltoid injection
Number of subjects: 18

Group type: COMPARATOR
Intervention: Injection diclofenac sodium 75 mg/3 ml (reference formulation) given intragluteally
Number of subjects: 18
Study: 16439873

Group type: EXPERIMENTAL
Intervention: 180 mg enfuvirtide, once-daily (QD)
Number of subjects: 37

Group type: COMPARATOR
Intervention: 90 mg enfuvirtide, twice-daily (BID)
Number of subjects: 37
Study: 12616182

Group type: EXPERIMENTAL
Intervention: Granisetron pretreatment (5 mL of 2 mg in 0.9% saline)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Lidocaine pretreatment (5 mL of 40 mg in 0.9% saline)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Saline pretreatment (5 mL of 0.9% saline)
Number of subjects: 150
Study: 10632644

Group type: COMPARATOR
Intervention: H. pylori eradication therapy
Number of subjects: 242
Study: 9160622

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study: 1474160

Group type: COMPARATOR
Intervention: Fasted state (30-mg OSR tablet every 12 hours)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fed state (30-mg OSR tablet every 12 hours)
Number of subjects: 0
Study: 6386008

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (GBE) (40 mg GBE; rökan)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 30559051

Group type: EXPERIMENTAL
Intervention: Lenalidomide maintenance (10 mg orally on days 1–21 of a 28‐day cycle)
Number of subjects: 1917

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 1917

Group type: EXPERIMENTAL
Intervention: Lenalidomide maintenance
Number of subjects: 1917
Study: 27873226

Group type: EXPERIMENTAL
Intervention: Standard EQ-5D-5L dimension order (Arm 1)
Number of subjects: 1080

Group type: EXPERIMENTAL
Intervention: Randomised order between respondents (Arm 2)
Number of subjects: 1080

Group type: EXPERIMENTAL
Intervention: Randomised within respondents (Arm 3)
Number of subjects: 1080

Group type: COMPARATOR
Intervention: Scale parameter testing across all arms
Number of subjects: 1080
Study: 26581327

Group type: COMPARATOR
Intervention: Delafloxacin 50, 100, 200, 400, 800, 1200, and 1600 mg (single ascending-dose study)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Delafloxacin 250 mg (single-dose crossover study)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Delafloxacin 250 mg (parallel group study)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Delafloxacin 100, 200, 400, 800, 1200 mg once daily for 5 days (multiple ascending-dose study)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Delafloxacin 900 mg (single-dose, randomized, 3-period crossover study)
Number of subjects: 52
Study: 25187580

Group type: EXPERIMENTAL
Intervention: Closing-wedge high tibial osteotomy
Number of subjects: 92

Group type: COMPARATOR
Intervention: Opening-wedge high tibial osteotomy
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 92
Study: 22889307

Group type: EXPERIMENTAL
Intervention: Flunarizine
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 19208560

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin plus aspirin (LMWH/ASA)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Aspirin alone (ASA)
Number of subjects: 88
Study: 18076814

Group type: EXPERIMENTAL
Intervention: Nurse-Physician Collaborative Partnership
Number of subjects: 37
Study: 15121747

Group type: EXPERIMENTAL
Intervention: EIH subjects at 8.1 mM lactate concentration
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: EIH subjects at 41 mM lactate concentration
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: EIH and non-EIH subjects combined at 8.1 mM lactate concentration
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: EIH and non-EIH subjects combined at 41 mM lactate concentration
Number of subjects: 15

Group type: COMPARATOR
Intervention: EIH and non-EIH subjects
Number of subjects: 15
Study: 11294428

Group type: EXPERIMENTAL
Intervention: Surgery with a tourniquet
Number of subjects: 56

Group type: COMPARATOR
Intervention: Surgery without a tourniquet
Number of subjects: 56
Study: 9723147

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg per day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Bright light (3000 lux, 2 h per day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo drug
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo light condition
Number of subjects: 40
Study: 8039533

Group type: EXPERIMENTAL
Intervention: Doxycycline carrageenate
Number of subjects: 24

Group type: COMPARATOR
Intervention: Doxycycline monohydrate
Number of subjects: 24

Group type: COMPARATOR
Intervention: Combination of omeprazole and doxycycline monohydrate
Number of subjects: 24
Study: 3195476

Group type: EXPERIMENTAL
Intervention: Cardiac counseling plus type A behavioral counseling
Number of subjects: 862

Group type: COMPARATOR
Intervention: Cardiac counseling
Number of subjects: 862
Study: 31813058

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 2 g/day for 6 months
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 30905018

Group type: EXPERIMENTAL
Intervention: Aeluropus lagopoides ecotypes
Number of subjects: 50

Group type: COMPARATOR
Intervention: Paspalum vaginatum (control)
Number of subjects: 50
Study: 28576901

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided popliteal sciatic (20 mL) and saphenal nerve (8 mL) PNB with ropivacaine 7.5 mg/mL
Number of subjects: 150

Group type: COMPARATOR
Intervention: Spinal anaesthesia (2 mL) with hyperbaric bupivacaine 5 mg/mL
Number of subjects: 150
Study: 25575697

Group type: EXPERIMENTAL
Intervention: Nicotine-containing tobacco
Number of subjects: 16

Group type: COMPARATOR
Intervention: Alcohol administration
Number of subjects: 16

Group type: COMPARATOR
Intervention: Denicotinized tobacco
Number of subjects: 16
Study: 23917335

Group type: EXPERIMENTAL
Intervention: Oral rehydration therapy with 2.5 % carbohydrate beverage (group A)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control group (water only, group B)
Number of subjects: 6
Study: 21403108

Group type: EXPERIMENTAL
Intervention: Clinical prognostic model for early prediction of outcome in GBS
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Clinical prognostic model validated in an independent cohort of 158 patients with GBS
Number of subjects: 397
Study: 19232024

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 16531899

Group type: EXPERIMENTAL
Intervention: Isometric handgrip exercise (HG) in normoxia
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Isometric handgrip exercise (HG) during isocapnic hypoxia
Number of subjects: 24

Group type: COMPARATOR
Intervention: Isocapnic hypoxia (chemoreflex activation)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Local circulatory arrest after HG in normoxia
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Local circulatory arrest after HG in hypoxia
Number of subjects: 24
Study: 13680386

Group type: EXPERIMENTAL
Intervention: Omeprazole (Losec)
Number of subjects: 15
Study: 10723972

Group type: EXPERIMENTAL
Intervention: Isotonic magnesium sulfate with salbutamol
Number of subjects: 35

Group type: COMPARATOR
Intervention: Normal saline with salbutamol
Number of subjects: 35
Study: 9169294

Group type: EXPERIMENTAL
Intervention: Subcutaneous sumatriptan
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19